The company combines plant microbial genetic engineering, protein purification, and controlled indoor agriculture to produce human recombinant proteins needed in therapeutic development. Their proprietary plant-based protein expression methods allow for the consistent expression and purification of large amounts of proteins, such as Recombinant Human Bone Morphogenetic Protein 2 (rhBMP-2), at a purity of 97%+. Compared to traditional methods, MNPHARM's expression methods offer lower overall costs, shorter production times, and higher quality proteins.